LAKE FOREST, Calif.—STAAR Surgical Company (NASDAQ: STAA), a global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, has announced preliminary net sales for the first quarter ended April 3, 2026. Net sales for the first quarter of 2026 are expected to be in excess of $90 million, compared with net sales of $42.6 million for the first quarter of 2025, according to the announcement from the company.
Quick Take
STAAR Surgical expects its first-quarter 2026 net sales to exceed $90 million, marking a dramatic increase from the $42.6 million reported during the same period in 2025. This preliminary outlook highlights a surge in demand for the company’s EVO family of Implantable Collamer Lenses (ICL).
Why It Matters
A year-over-year revenue increase of more than 100% signals a significant shift in the refractive surgery market toward lens-based vision correction. As the EVO ICL platform gains momentum, it suggests that both providers and patients are increasingly opting for phakic IOLs over or alongside traditional corneal refractive procedures. For practice owners and surgeons, these figures validate the commercial strength of the ICL category and may indicate a broader change in patient expectations for reversible, high-quality vision correction options.
Key Details
Practice Implications
Clinicians should prepare for increased patient awareness and demand for the EVO ICL as a primary refractive option.Practice owners may want to review their refractive surgery portfolio to ensure they are capturing the growth seen in the phakic IOL segment.The rapid growth suggests that the clinical conversation is shifting, and providers should be ready to discuss the benefits of lens-based correction versus traditional laser-based methods.
Who's Affected
What's Next
The company will release finalized financial results following the close of the quarter. Industry observers will be watching for specific data on geographic performance and whether this growth rate is sustainable throughout the remainder of 2026.
AI-generated summary — always read the original source for full context
No comments yet. Be the first to share your thoughts.
